<DOC>
	<DOCNO>NCT02858908</DOCNO>
	<brief_summary>The purpose study determine whether Tideglusib safe efficacious treatment adolescent adults congenital juvenile-onset Myotonic Dystrophy . The pharmacokinetics tideglusib primary metabolite also investigate .</brief_summary>
	<brief_title>Study Tideglusib Adolescent Adult Patients With Myotonic Dystrophy</brief_title>
	<detailed_description>The study currently open enrolment Newcastle Upon Tyne Hospitals NHS Trust subject age 16-45 year</detailed_description>
	<mesh_term>Myotonic Dystrophy</mesh_term>
	<criteria>Adolescents adult diagnosis congenital juvenileonset type 1 myotonic dystrophy ( DM1 ) Diagnosis must genetically confirm Subjects must male female age 12 year 45 year Subjects must Clinical Global Impression Severity ( CGIS ) score 4 great Screening Runin ( V2 ) Subjects must ambulatory able complete 10 metre walk/run test ( splint allow ) Subject 's legally authorize representative ( LAR ) must provide write informed consent must write consent assent ( age applicable developmentally appropriate ) subject studyrelated procedure conduct Nonambulatory ( full time ) wheel chair user Receiving stimulant medication Receiving medications/therapies stable ( change ) within 4 week prior Runin ( V2 ) Medical illness concern would cause investigator conclude subject able perform study procedures assessment would confound interpretation data obtain assessment . Current enrolment clinical trial investigational drug enrolment clinical trial investigational drug last 6 month Women child bear potential pregnant , lactate willing use protocol define acceptable contraception method sexually active surgically sterile . Gastrointestinal disease may interfere absorption , distribution , metabolism excretion study medication impact interpretability study result Current clinically significant ( determined investigator ) cardiovascular , renal , hepatic , endocrine respiratory disease Clinically significant heart disease ( opinion investigator ) second third degree heart block , atrial flutter , atrial fibrillation , ventricular arrhythmia , receive medication treatment cardiac arrhythmia A history chronic liver disease current range value Alanine transaminase ( ALT ) , clinically relevant hepatic steatosis clinical manifestation ongoing liver disease A history significant drug allergy ( StevenJohnson syndrome , anaphylaxis ) A history alcohol substance use disorder</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>